Enzyme Inhibitors with Broad Therapeutic Applications

Report Highlights

• During the forecast period, enzyme-inhibiting drugs are projected to be introduced for new indications including asthma and chronic obstructive pulmonary disease (COPD), pulmonary arterial hypertension, hepatitis C and intermittent claudication.
• Recent withdrawals of products in the COX-2 inhibitor class along with recent and future introductions of novel products in other classes will rearrange the market share of categories in the enzyme inhibitor sector. Overall, the market for products included in this report is expected to show an average annual growth rate (AAGR) of approximately 6.7% from 2005 to 2011, increasing from $29.2 billion to $43.1 billion.
• Of all the inhibitor categories, COX-2 and PDE4 will see increases in revenue share for the period 2005 to 2011. Cox-2 inhibitors' share will grow from 12.7% to 18.9%, while PDE4 inhibitors will increase from zero in 2005 to 3.6% in 2011.

INTRODUCTION

The aim of this report is to provide a range of information-from detailed market analyses through industry trends-to quantify and qualify the market for therapeutic enzyme inhibitors with large markets and/or broad therapeutic applications.

This report offers a broad detailed overview of enzyme inhibitors currently on the market and those in late-stage clinical trials. The information and analysis presented in this report are important assets in decision-making for managers involved in business development, marketing, market research, product development, mergers and acquisitions, licensing, business management, investment banking and deal creation, and to consultants to the pharmaceutical and biotechnology industry. The study provides a comprehensive analysis of the current markets for enzyme inhibiting drugs and, in particular, the market potential of promising drugs and technologies under development.

SCOPE OF STUDY

This report contains:

• The major current and emerging therapeutic markets for enzyme inhibitors used in human therapeutics,
• A discussion of the biochemistry for enzyme inhibitors and classes of enzyme inhibiting products with broad current or potential therapeutic applications or large markets,
• A synopsis of more than 100 enzyme inhibitors, including those currently marketed and those in Phase II or later development,
• An overview of the leading indications for available and emerging enzyme inhibitors. These include selected indications for asthma and chronic obstructive pulmonary disease (COPD), cardiovascular diseases, erectile dysfunction, gastrointestinal disorders, hepatitis B virus infection, hepatitis C virus infection, herpesvirus infections, human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS) and rheumatoid arthritis and related inflammatory diseases,
• Forecasts for the global market, through 2011,
• Company Profiles emphasizing companies that lead the pharmaceutical and biotechnology industry in the research and development of enzyme-inhibiting drugs.

METHODOLOGY

The base year for this study is 2005. Figures are based on revenue figures at the manufacturers' level and are projected at 2005 dollar value; that is, inflation is not computed into the projection figures.

Information to prepare this study was derived from information obtained from product managers, marketing strategists, research executives and others at leading pharmaceutical and biotechnology companies that compete in the market for enzyme inhibitors or which have products in development for this market.

INFORMATION SOURCES

The information and analyses presented in this report are based on an extensive survey of the biotechnology and pharmaceutical industries as well as a detailed examination of published literature and reports obtained from regulatory authorities, medical research institutions, pharmaceutical trade associations and national and world health organizations. Key information from the business literature was used as to obtain expert opinion on commercial potential and market sizes from industry professionals.

ABOUT THE AUTHOR

Lynn Gray has been a research analyst in biotechnology and life sciences since 1989 and with BCC since 1996. During that time, she has authored more than 20 research reports in the biomedical field for BCC Research.